BioInvent International
11.12.2021 23:46:53 CET | ACCESS Newswire | Press release
- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma
- Complete responses lasting beyond 18, 24 and 36 months
LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses. The data represent the status - to early November 2021 - of the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). They are published today in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021).
The ASH 2021 poster shows that BI-1206 in combination with rituximab provided an objective response rate (ORR) of 54%, with three complete responses and four partial responses in 13 patients evaluated for therapeutic benefit for the three indications (Mantle cell lymphoma, Marginal zone lymphoma and Follicular lymphoma) enrolled in the clinical study. The treatment stabilized disease in one additional patient, giving a disease control rate of 62% (8 out of 13 patients).
When considered alone, the response rate for Follicular lymphoma is particularly impressive: of nine evaluable patients, three developed a CR, three developed a PR and one patient had SD at the cut-off date, giving a 67% ORR and 78% DCR. Previous rituximab treatments without BI-1206 had failed in these patients, prior to participation in the trial all patients had relapsed on earlier lines of rituximab-containing treatments.
All complete responses have been sustained for extended periods, with the longest complete response enduring beyond 36 months. In two additional patients, complete responses have lasted beyond 12 and 24 months after end of treatment.
"The current data are highly encouraging and already show the benefit of BI-1206 in rescuing rituximab treatment in advanced NHL. Without BI-1206, rituximab did not work well in these patients. Based on our deep understanding of the immune mechanisms at play, these data indicate that BI-1206 not only restores the anti-tumor response but does it safely and in a prolonged manner in many patients, notably in Follicular lymphoma. Adjusting the dosing regimen of BI-1206 could lead to yet further improvements. We look forward to discussing all these aspects with investors during our forthcoming KOL call on December 17," said Martin Welschof, PhD, CEO of BioInvent.
BioInvent will host a key opinion leader (KOL) webinar on BI-1206 featuring Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current NHL treatment landscape and unmet medical needs. Senior management will discuss the data presented at ASH 2021 and first data from the Phase 1/2a study of BI-1206 in combination with pembrolizumab for the treatment of solid tumors. The webinar will take place on Friday, December 17, 2021, at 1:00 pm ET/7:00 pm CET.
To register for the webinar, please click here .
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors. BI-1206 has also received approval to start clinical trials in China.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent's poster is entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcyRIIB, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The poster is presented today December 11 at 5.30 pm ET (11:30 pm CET).
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Disclaimer - BioInvent
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-11 23:30 CET.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/677141/BioInvents-Latest-NHL-Data-at-ASH-Show-Increased-and-Sustained-Responses-to-BI-1206-in-Relapsed-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Opens Business & Bulk Ordering Ahead of Its Fall Prime Sale24.9.2026 06:50:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / September 24, 2026 / LiberNovo has opened its Business & Bulk Orders section ahead of the Fall Prime Sale, which runs at eu.libernovo.com and uk.libernovo.com. Team ordering goes live on 23 September, and seasonal sale pricing opens 30 September, with a flash sale on selected products on 6-7 October. Discounts reach up to 39% off, and every order is covered by 30-Day Price Protection. Ordering for a team, not a desk Business & Bulk Orders is live from today, covering orders of five chairs or more across the Omni and Maxis series - chairs alone or paired with a footrest - with tiered pricing at five to ten units and again at eleven or more. Discount rates and how they combine with the rest of the sale are set out on each regional page. The timing follows how companies buy: budgets close in the autumn, workstations get specified for the year ahead, and wellbeing programmes are agreed before January. Why October October is National Ergonomics Month. Hybri
OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions23.9.2026 14:25:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Uniso
SmartVendor Brings Autonomous Retail to the Czech Parliament; Clears Europe's Toughest Privacy Bar with SHEKEL WeightAI(TM)23.9.2026 11:20:00 CEST | Press release
PRAGUE, CZ / ACCESS Newswire / September 23, 2026 / SmartVendor today announced the deployment of an autonomous, AI-powered retail solution inside the Chamber of Deputies of the Parliament of the Czech Republic, built on the WeightAI™ platform from SHEKEL Scales Ltd., the weight-based AI technology and solution provider behind the next generation of autonomous retail. For public institutions across Europe, autonomous retail has presented a compliance contradiction: the technology that makes unattended stores work typically relies on cameras, and cameras mean GDPR risk. The Czech Parliament resolved that contradiction by choosing a solution built on WeightAI™. No cameras. No biometrics. No personal data captured at the point of purchase. Full GDPR compliance by design. The installation, deployed by SmartVendor on the Innovendi Elite platform, marks one of the first deployments of an autonomous AI-powered retail solution inside a major state institution in the Czech Republic. Members of
Fermi and TensorWave Agree to Extend Closing Date to October 31, 202622.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 22, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave") have signed a First Amendment to their Data Center Lease and Services Agreement (the "Lease"). The amendment extends the closing date under the Lease from September 30, 2026 to October 31, 2026. All other terms of the Lease remain unchanged and in effect. The Lease covers 222 megawatts (MW) of total facility power at Fermi's Project Matador campus and represents approximately $6.5 billion in expected total revenue over its initial 15-year term. Parties Working Constructively Toward Closing The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations sc
Leggett Dynamics Expands Asia Pacific Headquarters22.9.2026 17:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / September 22, 2026 / Leggett Dynamics today celebrated the grand opening of its expanded Asia Pacific headquarters in Shanghai, China marking the latest investment in the company's growth strategy for the region. The expanded facility includes 40 percent more office space, an innovation showroom and multifunctional space for training, events and enhanced collaboration among customers, suppliers and internal teams. "We're not simply expanding our Asia Pacific headquarters in Shanghai. We're expanding our capability to innovate faster, collaborate more closely and create greater value for our customers. This is critical in a hyper competitive market like China which is redefining the user experience in vehicles and turning comfort and motion into the new battleground globally for brand differentiation," said Marinela Cirstea, President of Leggett Dynamics. Today's grand opening in Shanghai reflects Leggett Dynamics' long-term commitment to Asia Pacific
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom